OverviewSuggest Edit

Kura Oncology is a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers. The Company's lead product candidate, tipifarnib, is a potent, selective and orally bioavailable inhibitor of farnesyl transferase. Tipifarnib is a new chemical entity, or NCE, and a member of a class of product candidates called farnesyl transferase inhibitors, or FTIs. Protein farnesylation is a key cell signaling process implicated in various cancer processes, including survival, growth and proliferation of tumor cells. 

TypePublic
Founded2007
HQSan Diego, US
Websitekuraoncology.com
Employee Ratings0

Latest Updates

Employees (est.) (Dec 2018)43(+5%)
Share Price (Mar 2019)$15.5 (-1%)

Kura Oncology Office Locations

Kura Oncology has an office in San Diego
San Diego, US (HQ)
11119 N Torrey Pines Rd #125, La Jolla
Show all (1)
Report incorrect company information

Kura Oncology Financials and Metrics

Kura Oncology Revenue

USD

Net income (FY, 2018)

(60.4m)

Market capitalization (15-Mar-2019)

591.2m

Closing stock price (15-Mar-2019)

15.5

Cash (31-Dec-2018)

16.1m

EV

582.6m
Kura Oncology's current market capitalization is $591.2 m.
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

General and administrative expense

22.7k6.0m7.9m9.4m15.8m

R&D expense

13.9m16.6m25.1m45.8m

Operating expense total

22.7k23.9m28.4m36.1m62.9m

EBIT

(22.7k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

General and administrative expense

4.5k4.1k5.2k1.5m1.8m2.4m1.8m1.7m2.1m2.2m2.3m3.4m3.7m4.3m

R&D expense

3.3m3.6m3.6m4.0m4.3m5.2m5.2m6.8m11.3m11.1m11.5m

Operating expense total

4.5k4.1k5.2k5.9m6.4m7.0m6.8m7.1m7.7m7.9m9.5m15.0m15.3m16.0m

EBIT

(4.5k)(4.1k)(5.2k)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

6.6k5.6k15.4m9.7m11.4m16.1m

Accounts Receivable

92.4m

Inventories

693.0k725.0k

Current Assets

86.9m68.8m94.6m181.2m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

10.6k6.2k4.9k11.2m16.3m12.1m6.8m10.6m12.2m23.3m26.5m17.7m20.6m

Inventories

909.0k

Current Assets

42.3m80.1m81.4m75.7m60.6m54.7m101.9m140.4m128.5m190.4m

PP&E

78.0k62.0k55.0k47.0k32.0k24.0k17.0k5.0k1.0k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(28.6k)(30.7k)(22.6m)(27.6m)(35.4m)(60.4m)

Depreciation and Amortization

20.0k31.0k30.0k10.0k

Inventories

(42.0k)(32.0k)

Accounts Payable

(1.5k)2.1k2.8m471.0k3.6m5.1m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(5.6m)(66.0k)(6.6m)(6.7m)(6.9m)(7.5m)(9.3m)

Inventories

909.0k

Accounts Payable

650.0713.08.2k10.7k2.5m3.7m3.1m3.3m4.2m3.7m4.2m6.2m
USDY, 2018

EV/CFO

-12 x

Financial Leverage

1.1 x
Show all financial metrics

Kura Oncology Operating Metrics

FY, 2016

Phase II Trials Products

1

Preclinical Phase Products

2
Show all operating metrics
Report incorrect company information

Kura Oncology News and Updates

Kura Oncology Reports Fourth Quarter and Full Year 2018 Financial Results

– Registration-directed trial of tipifarnib in HRAS mutant HNSCC underway –

Kura Oncology Announces FDA Clearance of Investigational New Drug Application for Menin-MLL Inhibitor KO-539

– KO-539 is a potent, selective small molecule inhibitor of the menin-MLL interaction –

Kura Oncology to Present at SVB Leerink Global Healthcare Conference

SAN DIEGO, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to particip…

Kura Oncology Reports Clinical Activity of Tipifarnib in Subsets of Pancreatic Cancer Associated with High CXCL12 Expression

– Tipifarnib is a CXCL12 pathway inhibitor that may provide clinical benefit in subsets of patients with pancreatic cancer –

Kura Oncology to Present at J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation at the 37th Annual J.P. Morgan Healthcare Conference. Troy Wilson, Ph.D., J.…

Kura Oncology Announces Proof of Concept in Angioimmunoblastic T-Cell Lymphoma, Validation of CXCL12 as a Therapeutic Target of Tipifarnib in Peripheral T-Cell Lymphoma

– Two CRs, four PRs (46% ORR) observed in advanced AITL patients in Phase 2 trial of tipifarnib in PTCL –
Show more
Report incorrect company information

Kura Oncology Blogs

Kura Oncology to Report Fourth Quarter and Full Year 2018 Financial Results

Kura Oncology to Report Fourth Quarter and Full Year 2018 Financial Results Content Import Tue, 02/26/2019 - 07:33 Kura Oncology to Report Fourth Quarter and Full Year 2018 Financial Results February 26, 2019 at 7:30 AM EST This release is a backfill from a Ne…

Tyler Van Buren

Tyler Van Buren ma.celeste.loy… Thu, 11/15/2018 - 13:11 Tyler Van Buren Piper Jaffray & Co.

Kura Oncology Adds Commercial Veteran Mary Szela to Board of Directors

Ms. Szela brings expertise in global brand development to Kura as company enters first registration-directed trial SAN DIEGO , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for

Kura Oncology to Participate in Two Upcoming Investor Conferences

SAN DIEGO , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to
Show more

Kura Oncology Frequently Asked Questions

  • When was Kura Oncology founded?

    Kura Oncology was founded in 2007.

  • How many employees does Kura Oncology have?

    Kura Oncology has 43 employees.

  • Who are Kura Oncology competitors?

    Competitors of Kura Oncology include NuCana, Caris Life Sciences and AmeriPharma.

  • Where is Kura Oncology headquarters?

    Kura Oncology headquarters is located at 11119 N Torrey Pines Rd #125, La Jolla, San Diego.

  • Where are Kura Oncology offices?

    Kura Oncology has an office in San Diego.

  • How many offices does Kura Oncology have?

    Kura Oncology has 1 office.